Copyright
©The Author(s) 2016.
World J Gastroenterol. Sep 21, 2016; 22(35): 8050-8059
Published online Sep 21, 2016. doi: 10.3748/wjg.v22.i35.8050
Published online Sep 21, 2016. doi: 10.3748/wjg.v22.i35.8050
Figure 1 Overall treatment outcome.
1Two hundred and sixty consecutive patients were treated with second generation direct acting antiviral (DAA) combinations; 14/260 patients lost to follow-up were not included in our analysis [modified intention-to-treat (mITT) analysis]. Additionally, 2 patients discontinued treatment prematurely, but achieved sustained virological response (SVR); accordingly these 2 patients also were counted as SVR12 patients.
- Citation: Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol 2016; 22(35): 8050-8059
- URL: https://www.wjgnet.com/1007-9327/full/v22/i35/8050.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i35.8050